Search
pharmaceutical monoclonal antibody
Adverse effects:
- serum sickness-like reaction to murine light & heavy chain variable regions when monocloncal Ab is a chimeric mouse + human monoclonal Ab with the monoclonal Ab containing murine light & heavy chain & human constant region
Specific
abciximab (ReoPro)
adalimumab (Humira, Idacio, Yusimry, Yuflyma)
alirocumab (Praluent)
anifrolumab (Saphnelo)
ansuvimab-zykl (Ebanga)
anti-Alzheimer monoclonal antibody
antineoplastic monoclonal antibody
atoltivimab; atoltivimab
axatilimab (Niktimvo)
bapineuzumab
basiliximab (Simulect)
belimumab (Benlysta)
benralizumab (Fasenra)
bezlotoxumab (Zinplava)
bimekizumab
bispecific antibody; bispecific monoclonal antibody
bococizumab
britumomab (Zevalin)
brodalumab (Siliq)
brolucizumab; brolucizumab-dbll (Beovu)
burosumab
canakinumab (Ilaris)
caplacizumab-yhdp (Cablivi)
certolizumab pegol (Cimzia)
crizanlizumab
crovalimab (Piasky)
daclizumab (Zinbryta)
denosumab (Prolia, Xgeva)
depemokimab
dupilumab (Dupixent)
Ebola monoclonal antibody (ZMapp)
eculizumab (Soliris)
efalizumab (Raptiva)
efgartigimod alfa-fcab (Vyvgart)
emapalumab; emapalumab lzsg (Gamifant)
emicizumab-kxwh (Hemlibra, ACE910)
eptinezumab
erenumab (Aimovig)
evinacumab-dgnb (Evkeeza)
evolocumab (Repatha)
faricimab-svoa (Vabysmo)
fremanezumab (Ajovy)
frunevetmab (Solensia)
galcanezumab (Emgality)
gemtuzumab
guselkumab (Tremfya)
ibalizumab-uiyk (Trogarzo)
idarucizumab (Praxbind)
inebilizumab-cdon (Uplizna)
infliximab (Remicade)
itolizumab
ixekizumab (Taltz)
lanadelumab (Takhzyro)
lebrikizumab (Ebglyss)
ligelizumab
maftivimab
marstacimab (Hympavzi)
mavrilimumab
mepolizumab (Nucala)
mirikizumab-mrkz (Omvoh)
monoclonal antibody AMG 145
monoclonal antibody combination
monoclonal antibody SAR2365535
monoclonal antibody to spike glycoprotein of SARS-CoV2 (COVID-19)
Muromonab-CD3 (OKT3)
natalizumab (Tysabri)
nemolizumab (Mitchga)
nirsevimab-alip (Beyfortus)
obiltoxaximab (Anthim)
ocrelizumab (Ocrevus)
odesivimab
olokizumab
omalizumab (Xolair)
palivizumab (Synagis)
pexelizumab
Polatuzumab Vedotin (POLIVY)
pozelimab-bbfg (Veopoz)
prasinezumab
ravulizumab (Ultomiris)
raxibacumab
reslizumab (Cinqair)
rhuMAB-E25
risankizumab (Skyrizi)
romosozumab (Evenity)
rozanolixizumab-noli (Rystiggo)
sarilumab (Kevzara)
satralizumab-mwge (Enspryng])
secukinumab (Cosentyx)
siltuximab (Sylvant)
sintilimab
spesolimab
sutimlimab-jome (Enjaymo)
tafasitamab-cxix (Monjuvi)
teprotumumab-trbw (Tepezza)
tezepelumab-ekko (Tezspire)
tildrakizumab (Ilumya)
tocilizumab; atlizumab (Actemra, RoActemra, Tofidence, Tyenne)
tralokinumab-ldrm (Adbry, Adtralza)
ublituximab (Briumvi)
ustekinumab (Stelara, Wezlana, Pyzchiva, Selarsdi)
vedolizumab (Entyvio)
vilobelimab (Gohibic)
General
monoclonal antibody
pharmaceutical agent
References
- Medical Knowledge Self Assessment Program (MKSAP) 19
Board Basics. An Enhancement to MKSAP19.
American College of Physicians, Philadelphia 2022